A detailed history of Engineers Gate Manager LP transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Engineers Gate Manager LP holds 77,791 shares of RXRX stock, worth $512,642. This represents 0.01% of its overall portfolio holdings.

Number of Shares
77,791
Previous 58,161 33.75%
Holding current value
$512,642
Previous $579,000 0.69%
% of portfolio
0.01%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$7.35 - $10.05 $144,280 - $197,281
19,630 Added 33.75%
77,791 $583,000
Q1 2024

May 15, 2024

BUY
$9.13 - $15.52 $427,192 - $726,180
46,790 Added 411.49%
58,161 $579,000
Q4 2023

Feb 14, 2024

BUY
$5.09 - $10.79 $57,878 - $122,693
11,371 New
11,371 $112,000
Q2 2022

Aug 15, 2022

SELL
$5.04 - $9.26 $413,884 - $760,431
-82,120 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$6.16 - $18.03 $505,859 - $1.48 Million
82,120 New
82,120 $588,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.19B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.